This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sellebjerg, F Articles by Sørensen, T L Search for Related Content PubMed PubMed Citation Articles by Sellebjerg, F Articles by Sørensen, T L Social Bookmarking                   What's this?

CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis

The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark, Copenhagen Multiple Sclerosis Centre, Copenhagen University Hospital, Copenhagen, Denmark, sellebjerg{at}dadlnet.dk

C Ross

Institute for Inflammation Research, Copenhagen University Hospital, Copenhagen, Denmark

N Koch-Henriksen

The Danish MS Treatment Registry, Copenhagen, Denmark and Department of Neurology, Aalborg Hospital, Aalborg, Denmark

P Soelberg Sørensen

Copenhagen Multiple Sclerosis Centre, Copenhagen University Hospital, Copenhagen, Denmark

J L Frederiksen

The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark

K Bendtzen

Institute for Inflammation Research, Copenhagen University Hospital, Copenhagen, Denmark

T L Sørensen

The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark

Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-ß-treated patients, we found that the hazard ratio for developing an attack was 2.8 in patients with CD26+CD4+T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-ß antibodies. CD26+CD4+T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-ß.

Key Words: CCR5 antigen • CD25 antigen • CD26 antigen • interferon treatment • multiple sclerosis • T cell immunology • treatment response

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F Sellebjerg, P Datta, J Larsen, K Rieneck, I Alsing, A Oturai, A Svejgaard, P Soelberg Sorensen, and L. Ryder Gene expression analysis of interferon-{beta} treatment in multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 615 - 621. [Abstract] [PDF]

				E. Wiesemann, M. Deb, C. Trebst, B. Hemmer, M. Stangel, and A. Windhagen Effects of interferon-{beta} on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-{beta} treatment in patients with multiple sclerosis Multiple Sclerosis, March 1, 2008; 14(2): 166 - 176. [Abstract] [PDF]